bullish
Terumo: Not Just an Opportune COVID Play but a Business with Solid Long-Term Prospects
286 Views20 Apr 2020 13:53
Terumo Corp (4543 JP) provides innovative medical solutions through its extensive business portfolio which ranges from vascular intervention and...
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 11-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Gilead: Will Immunomedics Be Gilead’s Next Pharmasset?30 Sep 2020
- Terumo: Pandemic Impacts Q1 but Recovery Is Expected in the 2nd Half10 Aug 2020
- Gilead to Acquire a Stake in Arcus Biosciences; Offer May Come at a Large Premium21 Apr 2020
- M3 Inc: M&A Deals to Support Global Expansion While Medical Platform Offers Solid LT Growth27 Mar 2020
- Fujifilm’s Shares Hit Daily Upper Limit on COVID Trial Drug Boost18 Mar 2020
x